Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 2Hyperthermia 2Breast Neoplasms 2Uveal Melanoma 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Retinoblastoma 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Immune Checkpoint Inhibitors 30Capecitabine 30Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Hyperthermia, Induced × Clear all
NCT07062055 2026-05-08

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
54 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡